Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)

Treatment: Participant will receive brontictuzumab by vein over 30 minutes one time every 3 weeks. Clinic Visits: On Day 1 of Cycle 1 and then every 3 weeks from then on: * Participant will have a physical exam * Blood (about 3 teaspoons) will be drawn for routine tests. Every 6 weeks, participant will have an MRI and CT scan to check the status of the disease. Length of Treatment: Participant may continue taking brontictuzumab for as long as the doctor thinks it is in their best interest. Participant will no longer be able to take the drug if the disease gets worse, they develop another illness that prevents receiving more treatment, or if intolerable side effects occur. Brontictuzumab is not FDA approved or commercially available. It is currently being used for research purposes only.